CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Povidone-Iodine 0.5%Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1265 Isotonic saline 0.9% Wiki 1.00
drug1886 Povidone-Iodine 2% Wiki 1.00
drug1853 Placebo oral tablet Wiki 0.19
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

NCT04347954 COVID-19 Drug: Povidone-Iodine 2% Drug: Povidone-Iodine 0.5% Drug: Isotonic saline 0.9%

Primary Outcomes

Description: Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynx

Measure: Mean change in viral titers of SARS-CoV-2

Time: Day 1 (baseline), Day 1 (4 hours), Day 5

Secondary Outcomes

Description: Adverse effects of interest include: Nasal burning/pain Headaches Ear pain Sneezing Nose bleeds

Measure: Frequency of adverse effects of interest after nasal sprays

Time: Up to 5 days

Description: Symptoms of interest include: Fever Fatigue Change in smell Change in taste Nasal obstruction Chills Sore throat

Measure: Frequency of symptoms related to SARS-CoV-2

Time: Up to 5 days

Description: Self report by participants (survey) of estimated doses completed.

Measure: Compliance with study drug administration

Time: Up to 5 days

Description: Participants scratch the cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normal, mild, moderate, or severe microsmia (loss of smell).

Measure: Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)

Time: Day 1 (baseline), Day 30


No related HPO nodes (Using clinical trials)